Among AML-pCT patients previously affected by BC, we found a higher frequency of FLT3-ITD (17.6%) and NPM1 mutations (14.3%) but a lower frequency of TP53 mutations (8.3%) compared to a genetic study on BC and gynecological cancer survivors who developed AML-pCT [28]. The gene discussed is NPM1; the disease is breast cancer.